Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.60 |
| ▸ | TLR2 | O60603 | 2/20 | 0.56 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3236374 | 1.00 | CASP3 (0.60) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL3673319 | 1.00 | CASP3 (0.60) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL3378520 | 1.00 | CASP3 (0.60) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL30802531 | 1.00 | CASP3 (0.60) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL31538719 | 0.90 | CASP3 (0.55) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL19542133 | 0.90 | CASP3 (0.55) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL7713104 | 0.88 | CASP3 (0.62) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL7726774 | 0.88 | CASP3 (0.62) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL120255 | 0.88 | TLR2 (0.59) | CASP3TLR2MDM4TP53MDM2 | |
| SCHEMBL7532853 | 0.88 | TLR2 (0.59) | CASP3TLR2MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510576-A | Method for preparing palmitoyl tripeptide-38 | 富乐马鸿凯（大连）医药有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20250263440-A1 | CD38-BINDING AGENTS AND USES THEREOF | PEPTIDREAM INC. (JP) | 2025-08-21 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-29 | — | — | US | disclosed |
| CN-119954773-A | PSMA compounds, pharmaceutical compositions comprising the same and uses thereof | 苏州威智创科生物有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119954906-A | CD38 binding agents and uses thereof | 肽梦想株式会社 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025092841-A1 | PSMA COMPOUND, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 山东威智知科药业有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-22 | — | — | US | disclosed |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-03 | — | — | US | disclosed |
| WO-2022260135-A1 | METHOD FOR PRODUCING FLUORESCENT PROBE LIBRARY USING SOLID-PHASE EXTRACTION AND METHOD OF MEASURING ENZYME ACTIVITY USING SAME | 国立大学法人 東京大学 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022234852-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4043478-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-08-17 | — | — | EP | disclosed |
| EP-3993874-A1 | CD38-BINDING AGENTS AND USES THEREOF | PeptiDream Inc. (JP) | 2022-05-11 | — | — | EP | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171494-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | CASP3 1091/4885TLR2 4042/4885MDM4 4142/4885 |
| US-20250263440-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, IGSF11, MCL1 | CASP3 2781/4885TLR2 3833/4885MDM4 1302/4885 |
| US-12281141-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | CASP3 1091/4885TLR2 4042/4885MDM4 4142/4885 |
| US-20230138226-A1 | METHOD FOR SYNTHESIZING PEPTIDE CONTAINING N-SUBSTITUTED AMINO ACID | NPPA, VIP, DNPEP | CASP3 1091/4885TLR2 4042/4885MDM4 4142/4885 |
| US-11542299-B2 | Method for synthesizing peptide containing N-substituted amino acid | NPPA, VIP, DNPEP | CASP3 1091/4885TLR2 4042/4885MDM4 4142/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CASP3 3906/4885TLR2 3821/4885MDM4 441/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885TLR2 3462/4885MDM4 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.